Market Newsdesk

HONG KONG, SHANGHAI, FLORHAM PARK, N.J., July 27, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq: AZN) have initiated a Phase II study of ORPATHYS^® (savolitinib), an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, in patients with advanced or metastatic MET amplified gastric cancer (“GC”) or adenocarcinoma of the gastroesophageal junction (“GEJ”). The first patient was dosed on July 27, 2021.

The Phase II trial is an open-label, two-cohort, multi-center study to evaluate the efficacy, safety and pharmacokinetics (“PK”) of ORPATHYS^® in locally advanced or metastatic GC or GEJ patients whose disease progressed after at least one line of standard therapy. The primary endpoint is objective response rate (“ORR”) as assessed by an independent review committee. Other endpoints include 12-week and 6-month progression-free survival (“PFS”) rates, median PFS, duration of response (“DoR”), disease control rate (“DCR”), median overall survival (“OS”), safety, PK and quality of life.

The Beijing Cancer Hospital is the lead institution of this study. The lead investigator is Dr Shen Lin. For more information, please see clinicaltrials.gov identifier: NCT04923932.

MET-driven gastric cancer has a very poor prognosis.¹ This trial follows multiple Phase II studies that have been conducted in Asia to study ORPATHYS^® in MET-driven gastric cancer patients, including VIKTORY.² VIKTORY is an investigator initiated Phase II umbrella study in gastric cancer in South Korea in which a total of 715 patients were successfully sequenced into molecular-driven patient groups, including those with MET amplified gastric cancer. Patients whose tumors harbor MET amplification were treated with ORPATHYS^® monotherapy, reporting an ORR of 50% (10/20, 95% CI: 28.0, 71.9).

It is estimated that MET amplification accounts for approximately 4-6% of GC patients.^2,3 The annual incidence of MET amplification GC is estimated to be approximately 24,000 in China.⁴

About ORPATHYS

^®

ORPATHYS^® is an oral, potent, and highly selective MET tyrosine kinase inhibitor (“TKI”) that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations) or gene amplification.

ORPATHYS^® is marketed in China for the treatment of patients with non-small cell lung cancer (“NSCLC”) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy. It is currently under clinical development for multiple tumor types, including lung, kidney, and gastric cancers, as a single treatment and in combination with other medicines.

In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing agreement to jointly develop and commercialize ORPATHYS^®. Joint development in China is led by HUTCHMED, while AstraZeneca leads development outside of China. HUTCHMED is responsible for the marketing authorization, manufacturing and supply of ORPATHYS^® in China. AstraZeneca is responsible for the commercialization of ORPATHYS^® in China and worldwide. Sales of ORPATHYS^® will be recognized by AstraZeneca.

ORPATHYS

^®

development in NSCLC

Phase II study of ORPATHYS



^®



monotherapy in MET Exon 14 skipping alteration NSCLC (


NCT02897479


)
– In June 2021, ORPATHYS^® was granted drug registration conditional approval by the National Medical Products Administration of China (NMPA) for MET Exon 14 skipping alteration NSCLC. The approval was based on the results of a Phase II study in China; results of this study were presented during the American Society of Clinical Oncology ASCO20 Virtual Scientific Program in May 2020, and updated results were published in The Lancet Respiratory Medicine⁵ in June 2021. At a median follow up of 17.6 months, ORPATHYS^® demonstrated an objective response rate (“ORR”) of 42.9% (95% confidence interval [CI] 31.1-55.3) and median progression-free survival (“PFS”) of 6.8 months (95% CI 4.2-9.6) in the overall trial population. PFS was clinically meaningful across subgroups, and ORR results were consistent regardless of prior treatment or tumor histology, including in patients with the pulmonary sarcomatoid carcinoma (PSC) subtype (40.0%, 95% CI 21.1-61.3) and patients with other NSCLC subtypes (44.4%, 95% CI 29.6-60.0). Disease control rate (“DCR”) in the overall trial population was 82.9% (95% CI 72.0-90.8). The safety and tolerability profile of ORPATHYS^® was consistent with previous trials, and no new safety signals were identified. Continued approval is contingent upon the successful completion of a confirmatory trial in this patient population (NCT04923945).

SAVANNAH Phase II study of ORPATHYS



^®



in combination with TAGRISSO


^®


in patients who have progressed following TAGRISSO



^®



due to MET amplification or overexpression (


NCT03778229


)
– This is a single-arm, open-label, global study in epidermal growth factor receptor (“EGFR”) mutation positive NSCLC patients with MET amplified/overexpressed tumors following progression after treatment with TAGRISSO^®, an EGFR TKI owned by AstraZeneca.

Phase III study of ORPATHYS



^®



in combination with TAGRISSO



^®



in patients who have progressed following EGFR TKI treatment due to MET amplification (in planning)
– This is a randomized, open-label study in China in EGFR mutation positive NSCLC patients with MET amplified tumors following progression after treatment with any EGFR TKI.

Phase III study of ORPATHYS



^®



in combination with TAGRISSO



^®



in treatment naïve patients with EGFR mutant positive NSCLC with MET overexpression (in planning)
– This is a randomized, blinded study in China in untreated, unresectable or metastatic patients with EGFR mutation positive NSCLC with MET positive tumors.

ORPATHYS

^®

development in kidney cancer

SAVOIR randomized, controlled study of ORPATHYS



^®



monotherapy in MET-driven papillary renal cell carcinoma (“RCC”) (


NCT03091192


)
– In May 2020, data from 60 patients in this global study of ORPATHYS^® monotherapy compared with sunitinib monotherapy in MET-driven papillary RCC was presented at the ASCO 2020 Program and published simultaneously in JAMA Oncology⁶. ORPATHYS^® demonstrated encouraging activity, including an ORR of 27% versus 7% for sunitinib, with no ORPATHYS^® responding patients experiencing disease progression at data cut-off, and an encouraging overall survival (“OS”) hazard ratio of 0.51 (95% CI: 0.21–1.17; p=0.110) with median not reached at data cut-off.

CALYPSO Phase I/II study of ORPATHYS



^®



in combination with IMFINZI



^®



PD-L1 inhibitor in RCC (


NCT02819596


)
– The CALYPSO study is an investigator initiated open-label Phase I/II study of ORPATHYS^® in combination with IMFINZI^®, a PD-L1 antibody owned by AstraZeneca. The study is evaluating the safety and efficacy of the ORPATHYS^®/IMFINZI^® combination in patients with papillary RCC and clear cell RCC. An analysis of 41 patients enrolled in the PRCC cohort of in this study was presented at the 2021 ASCO Annual Meeting⁷, showing a confirmed response rate in 14 MET-driven patients of 57%, with a median duration of response (“DoR”) of 9.4 months, median PFS of 10.5 months and median OS of 27.4 months. No new safety signals were seen.

Phase III study in combination with IMFINZI



^®



PD-L1 inhibitor in MET-driven, unresectable and locally advanced or metastatic PRCC (in planning)

– Based on the encouraging results of the SAVOIR and CALYPSO studies, we intend to initiate a global Phase III, open-label, randomized, controlled study of ORPATHYS^® plus IMFINZI^® versus sunitinib monotherapy versus IMFINZI^® monotherapy in patients with MET-driven, unresectable and locally advanced or metastatic PRCC.

ORPATHYS

^®

development in other cancer indications

ORPATHYS^® opportunities are also continuing to be explored in multiple other MET-driven tumor settings via investigator-initiated studies including non-small cell lung cancer, gastric cancer and colorectal cancer.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,300 personnel has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of ORPATHYS

^®

for the treatment of patients with gastric cancer, the further clinical development of ORPATHYS

^®

in this and other indications, its expectations as to whether clinical studies of ORPATHYS

^®

would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the sufficiency of its data to support New Drug Application approval of ORPATHYS

^®

for the treatment of patients with gastric cancer in China, its potential to gain expeditious approvals for ORPATHYS

^®

in other jurisdictions such as the U.S., E.U. or Japan, the safety profile of ORPATHYS

^®

, the potential for ORPATHYS

^®

to become a new standard of care for gastric cancer patients, its ability to implement and complete its further clinical development plans for ORPATHYS

^®

, its potential commercial launch of ORPATHYS

^®

in China and other jurisdictions, the timing of these events, and the impact of the COVID-19 pandemic on general economic, regulatory and political conditions. In addition, as certain studies rely on the use of TAGRISSO

^®

and IMFINZI

^®

as combination therapeutics with ORPATHYS

^®

, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of TAGRISSO

^®

and IMFINZI

^®

. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the U.S. Securities and Exchange Commission, on AIM and with The Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President	+852 2121 8200
Annie Cheng, Vice President	+1 (973) 567 3786
Media Enquiries
Americas – Brad Miles, Solebury Trout	+1 (917) 570 7340 (Mobile) [email protected]
Europe – Ben Atwell / Alex Shaw, FTI Consulting	+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) [email protected]
Asia – Zhou Yi, Brunswick	+852 9783 6894 (Mobile) [email protected]
Nominated Advisor
Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) Limited	+44 (20) 7886 2500

__________________________________________________________________________________________________________

¹ Catenacci DV, Ang A, Liao WL, et al. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer. 2017;123(6):1061-1070. doi:10.1002/cncr.30437
² Lee J, Kim ST, Kim K, et al. Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. Cancer Discov. 2019;9(10):1388-1405. doi:10.1158/2159-8290.CD-19-044
³ Van Cutsem E, Karaszewska B, Kang YK, et al. A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors. Clin Cancer Res. 2019;25(8):2414-2423. doi:10.1158/1078-0432.CCR-18-1337
⁴ Global Cancer Observatory. China Fact Sheet. gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf.
⁵ Lu S, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med. 2021 Jun 21:S2213-2600(21)00084-9. doi: 10.1016/S2213-2600(21)00084-9.
⁶ Choueiri TK, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Aug 1;6(8):1247-1255. doi: 10.1001/jamaoncol.2020.2218.
⁷ Powles T, et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). J Clin Oncol 37, 2019 (suppl 7S; abstr 545). doi: 10.1200/JCO.2019.37.7_suppl.545.

NEWARK, Calif., July 27, 2021 (GLOBE NEWSWIRE) — ShotSpotter, Inc., a leader in precision policing technology solutions that enable law enforcement to more effectively respond to, investigate, and deter crime, responds below to false and misleading allegations that VICE published on July 26, 2021:

To the Communities We Serve:

Recently, VICE published outrageous allegations that create a false narrative about our technology, review and forensic process that undermine the important work ShotSpotter does every day to help combat the gun violence epidemic.

First, ShotSpotter forensic evidence is 100% reliable and based entirely on the facts and science. ShotSpotter has never altered the information in a court-admissible detailed forensic report based on fitting a police narrative.

It is important to understand that there are two separate and equally important services that ShotSpotter provides relating to gunshot sounds. The first is to detect and report potential gunshots. These are real-time notifications that detect and alert police to a specific gunfire incident. The goal is to quickly determine when and where gunfire has occurred within a city’s coverage area and to create a rapid and precise police response. This process is 97% accurate based on customers reporting back to the company for the years 2019 and 2020.

ShotSpotter also is available to provide, a detailed forensic report that is prepared as courtroom evidence and for expert witness testimony. As opposed to the detect and report service, the forensic service requires a detailed forensic analysis of the gunfire. It provides a more detailed analysis of gunfire. As an example, the immediate detect and report service may or may not report multiple gunshots, the forensic analysis would. Whether gunfire occurs is important to the detect and report service, the number of gunshots may or may not be important to a trial. And it is for this reason that ShotSpotter offer the additional service.

This additional service results in a court-admissible analysis of a gunfire incident. Our expert forensic analysts spend on average eight hours per incident to compile a court-admissible report using specialized tools that are different than for alerts that is 100% exact on rounds fired, timing, sequence and location of shots fired – something they can testify to in court under oath.

ShotSpotter evidence and expert witness testimony have been successfully admitted in 190 court cases in 20 states. ShotSpotter evidence has prevailed in ten successful Frye challenges and one successful Daubert challenge throughout the United States. Our data compiled with our expert analysis help prosecutors make convictions.

The detailed forensic report is never altered because it is a completely separate process from the alerts. Forensic analysis may uncover additional information relative to a real-time alert such as more rounds fired or an updated timing or location upon more thorough investigation by forensic analysis. We respond to requests to further investigate an incident for a forensic report only to provide the facts that we can determine and not to fit a predetermined narrative. This is about being diligent and providing the appropriate evidence and insights in the evidentiary chain of custody and nothing more.

The idea that ShotSpotter “alters” or “fabricates” evidence in any way is an outrageous lie and would be a criminal offense. We follow the facts and data for our forensic analysis. Period.

Second, ShotSpotter Will Not Tolerate False Characterizations of the Two Cases

VICE

Cited

VICE

’s article falsely alleged that in the

Williams

case in Chicago, Illinois, prosecutors withdrew ShotSpotter evidence because it would not meet scientific evidentiary standards because it had been altered. This is false. No evidence provided by ShotSpotter was altered. ShotSpotter forensic analysts evaluated the incident to create a court-admissible forensic report.

The issue was this. The prosecutor’s theory was that the gunshot occurred in the victim’s car. Once ShotSpotter learned of this theory, it approached the prosecutor and informed him that the ShotSpotter evidence could not support this theory. ShotSpotter has long informed the public, prosecutors and police that ShotSpotter cannot detect gunshots that occur in a car or a building. In short, the prosecutor’s theory of the case was inconsistent with the evidence. ShotSpotter so informed the prosecutor. Far from a case of tampering with evidence, ShotSpotter informed the prosecutor that the evidence it had would not support the prosecutor’s theory.

In a similar manner the article misconstrues facts relating to another case. The article also falsely and without any substantiation alleged that ShotSpotter fabricated evidence or altered audio files in the Simmons case in Rochester, New York. The audio files ShotSpotter recorded and used during the trial were secured and preserved using industry-standard forensic procedures. Audio files submitted as evidence were reviewed by our forensic analysts to create a court-admissible forensic report. They were never altered by ShotSpotter. We are currently engaged in a lawsuit and are vigorously defending our position.

Third, the ShotSpotter system is highly accurate at detecting outdoor gunshots and benefits communities battling gun violence.

The article falsely twisted the words of a ShotSpotter forensic expert to suggest our accuracy rates are the product of our marketing or sales departments. Nothing could be further from the truth. In 2019 and 2020, the ShotSpotter system had a 97% accuracy rate for real-time across all customers, a figure derived directly from police department reports. At the same time, ShotSpotter promises them a 90% accuracy rate in our service level agreements (SLA) because our customers expect and deserve a minimum accuracy rate. Our system has been tested to ensure that we correctly convey our system’s efficacy to our customers. In addition, ShotSpotter rigorously trains and tests every individual reviewing real-time gunfire incidents at the company to ensure they are performing at a level consistent with the company’s quality objectives.

VICE’s attempted takedown is a sad distraction from the issue at hand: addressing gun violence to keep our communities safe. In recent weeks, shootings have surged in many parts of the country, robbing us of American lives. ShotSpotter is a tool for helping law enforcement put a stop to this senseless violence and break the cycle of the normalization of gun violence in our communities. We will not tolerate our company being maligned and will vigorously defend our work in making communities safer for all.

Media Contact:

Trident DMG
Caroline Beckmann
202-440-1783
[email protected]

• Year-to-Date Net Income Increases 20% to $21.57 Million
• Quarterly Return on Average Assets of 1.63%
• Quarterly Return on Average Equity of 14.02%
• Announces $0.21 Quarterly Cash Dividend and a $0.10 Special Dividend

HOQUIAM, Wash., July 27, 2021 (GLOBE NEWSWIRE) — Timberland Bancorp, Inc. (NASDAQ: TSBK) (“Timberland” or “the Company”), the holding company for Timberland Bank (the “Bank”), today reported that net income increased 13% to $7.02 million for the quarter ended June 30, 2021 from $6.21 million for the comparable quarter one year ago, which quarter was affected by a $1.00 million ($790,000 after income taxes) provision to the loan loss reserves, and decreased $227,000, or 3%, from $7.25 million for the preceding quarter. Earnings per diluted common share (“EPS”) increased 12% to $0.83 for the current quarter from $0.74 for the comparable quarter one year ago and decreased 3% from $0.86 for the preceding quarter.

For the first nine months of fiscal 2021, Timberland earned a record $21.57 million, or $2.55 per diluted common share, a 20% increase in net income and EPS from $17.91 million, or $2.12 per diluted common share for the first nine months of fiscal 2020, which nine month period was affected by a $3.20 million ($2.53 million after income taxes) provision to the loan loss reserves.

Timberland’s Board of Directors declared a quarterly cash dividend to shareholders of $0.21 per common share and a special cash dividend of $0.10 per common share. Both dividends are payable on August 27, 2021, to shareholders of record on August 13, 2021.

“We are pleased to report strong quarterly net income and record profitability for the first nine months of fiscal 2021,” stated Michael Sand, President and CEO. “Paycheck Protection Program (“PPP”) loan proceeds and federal stimulus payments contributed to strong deposit growth of $204.11 million during the past twelve months including $40.79 million during the quarter just ended. The 15% increase in deposits year-over-year has increased the Bank’s liquidity significantly above normal levels. Net loans outstanding, net of PPP loans, increased this quarter at an annualized rate of 6% and we continue to be encouraged by the increased business activity we are seeing in our markets.”     

“Staff continues to be diligently and successfully engaged in the task of filing SBA loan forgiveness applications for businesses in our communities that obtained PPP financing through Timberland Bank. During the quarter ended June 30, 2021, PPP loans were reduced by $42.54 million and $95.63 million of PPP loans remained on the Bank’s balance sheet at quarter end. Timberland participated in the origination of PPP loans during every phase of the program and originated $192.43 million of PPP loans for existing as well as new clients.”  

“Timberland’s Board is also pleased to have announced today the appointment of Parul Bhandari to Timberland’s Board of Directors. During the past few years Timberland has sought to acquire directors with strong technology backgrounds and Ms. Bhandari is the third Director with significant experience and expertise in the technology sector to join Timberland’s Board. She brings to Timberland 20 plus years of experience scaling businesses through data, cloud and AI powered digital transformation. Ms. Bhandari leads the Partner Strategy for the Worldwide Media and Communications Industry group at Microsoft. Additional background information is included in a separate press release published today. With Ms. Bhandari’s appointment, Timberland now has eight independent directors, equally balanced between men and women. We look forward to Ms. Bhandari’s participation and counsel as a member of Timberland’s Board of Directors.”                       

Third Fiscal Quarter 2021 Earnings and Balance Sheet Highlights (at or for the period ended June 30, 2021, compared to March 31, 2021 or June 30, 2020):

Earnings Highlights:

• Net income increased 13% to $7.02 million for the current quarter from $6.21 million for the comparable quarter one year ago and decreased 3% from $7.25 million for the preceding quarter;
• EPS increased 12% to $0.83 for the current quarter from $0.74 for the comparable quarter one year ago and decreased 3% from $0.86 for the preceding quarter;
• Net income increased 20% to $21.57 million for the first nine months of fiscal 2021 from $17.91 million for the first nine months of fiscal 2020;
• EPS increased 20% to $2.55 for the first nine months of fiscal 2021 from $2.12 for the first nine months of fiscal 2020;
• Return on average equity (“ROE”) and return on average assets (“ROA”) for the current quarter were 14.02% and 1.63%, respectively;
• Net interest margin (“NIM”) was 3.22% for the current quarter compared to 3.21% for the preceding quarter and 3.63% for the comparable quarter one year ago; and
• The efficiency ratio was relatively stable at 49.43% for the current quarter compared to 48.99% for the preceding quarter and 49.96% for the comparable quarter one year ago.

Balance Sheet Highlights:

• Total assets increased 14% year-over-year and 2% from the prior quarter;
• Total deposits increased 15% year-over-year and 3% from the prior quarter;
• Net loans receivable (including SBA PPP loans) decreased 1% year-over-year and decreased 3% from the prior quarter;
• Net loans receivable (excluding SBA PPP loans) increased 2% year-over-year and increased 2% from the prior quarter;
• Non-performing assets to total assets ratio improved to 0.14%; and
• Book and tangible book (non-GAAP) values per common share increased to $24.36 and $22.39, respectively, at June 30, 2021.

Operating Results

Operating revenue (net interest income before the provision for loan losses plus non-interest income) increased 1% to $17.42 million for the current quarter from $17.34 million for the comparable quarter one year ago and decreased slightly from $17.45 million for the preceding quarter. Operating revenue increased 3% to $52.46 million for the first nine months of fiscal 2021 from $50.84 million for the comparable period one year ago.

Net interest income increased 5% to $13.16 million for the current quarter from $12.48 million for the comparable quarter one year ago and increased 5% from $12.57 million for the preceding quarter.   Timberland’s NIM for the current quarter was 3.22% compared to 3.21% for the preceding quarter and 3.63% for the comparable quarter one year ago.   NIM compression over the past year has largely been a result of the low interest rate environment and an increase in the level of liquidity held in overnight funds. The NIM for the current quarter was increased by approximately 13 basis points due to the accretion of $84,000 of the fair value discount on loans acquired in the South Sound Acquisition and the collection of $443,000 in pre-payment penalties, non-accrual interest, and late fees. The NIM for the preceding quarter was increased by approximately six basis points due to the accretion of $86,000 of the fair value discount on loans acquired in the South Sound Acquisition and the collection of $129,000 in pre-payment penalties, non-accrual interest and late fees. The NIM for the comparable quarter one year ago was increased by approximately ten basis points due to the accretion of $170,000 of the fair value discount on loans acquired in the South Sound Acquisition and the collection of $177,000 in pre-payment penalties, non-accrual interest and late fees.

U.S. Small Business Administration (“SBA”) PPP loans contribute to interest income through the 1.00% interest rate earned on outstanding loan balances and also through the accretion of loan origination fees into interest income over the life of each PPP loan. At June 30, 2021, Timberland had SBA PPP deferred loan origination fees of $3.31 million remaining to be accreted into interest income over the remaining life of the loans. The following table details the interest income recognized from SBA PPP loans:

SBA PPP Loan Income ($ in thousands)
	Three Months Ended
	June 30, 2021				March 31, 2021				June 30, 2020
Interest income	$	293			$	306			$	240
Loan origination fee accretion		1,296				1,143				443
Total SBA PPP loan income	$	1,589			$	1,449			$	683

Net interest income increased 1% to $38.75 million for the first nine months of fiscal 2021 from $38.36 million for the first nine months of fiscal 2020. Timberland’s net interest margin for the first nine months of fiscal 2021 was 3.30%, compared to 4.08% for the first nine months of fiscal 2020.

No provision for loan losses was made during the current and preceding quarter, compared to a $1.00 million ($790,000 after income taxes) provision for loan losses for the comparable quarter one year ago. No provision for loan losses was made during the nine months ended June 30, 2021 compared to a $3.20 million ($2.53 million after income taxes) provision for loan losses for the nine months ended June 30, 2020.

Non-interest income decreased 12% to $4.27 million for the current quarter from $4.86 million for the comparable quarter one year ago and decreased 13% from $4.89 million for the preceding quarter. The decrease in non-interest income compared to the preceding quarter was primarily due to a $179,000 valuation allowance on loan servicing rights for the current quarter (compared to a $438,000 valuation recovery on servicing rights for the preceding quarter) and a $151,000 decrease in gain on sales of loans. These decreases were partially offset by a $126,000 increase in ATM and debit card interchange transaction fees. The valuation allowance on loan servicing rights was primarily due to an increase in projected mortgage prepayment speeds due to declines in mortgage interest rates during the quarter. The increase in ATM and debit card interchange transaction fee income was primarily due to increased debit card activity. The decrease in gain on sales of loans compared to the prior quarter was primarily due to a decrease in the average pricing spread on loans sold during the current quarter. Fiscal year-to-date non-interest income increased 10% to $13.71 million from $12.47 million for the first nine months of fiscal 2020.

Total operating expenses for the current quarter increased 1% to $8.61 million from $8.55 million for the preceding quarter and decreased 1% from $8.66 million for the comparable quarter one year ago.   The increase in operating expenses compared to the preceding quarter was primarily due to an $81,000 increase in professional fees, a $73,000 increase in OREO expense, a $58,000 increase in loan administration expenses, a $44,000 increase in deposit operations expense and smaller increases in several other expense categories. These increases were partially offset by a $224,000 decrease in salaries and employee benefit expense and smaller decreases in several other expense categories.   The efficiency ratio for the current quarter was 49.43% compared to 48.99% for the preceding quarter and 49.96% for the comparable quarter one year ago.   Fiscal year-to-date operating expenses increased 1% to $25.57 million from $25.32 million for the first nine months of fiscal 2020. The efficiency ratio for the first nine months of fiscal 2021 improved to 48.75% from 49.81% for the first nine months of fiscal 2020.

The provision for income taxes for the current quarter increased $135,000 to $1.79 million from $1.65 million for the preceding quarter, primarily due to a $143,000 decrease in the tax benefit from stock option dispositions.   Timberland’s effective income tax rate was 20.3% for the quarter ended June 30, 2021 compared to 18.6% for the quarter ended March 31, 2021. The fiscal year-to-date provision for income taxes increased $916,000 to $5.32 million for the first nine months of fiscal 2021 from $4.40 million for the first nine months of fiscal 2020, primarily due to higher income before income taxes. Timberland’s effective income tax rate for the nine month periods ended June 30, 2021 and 2020 was 19.8%.  

Balance Sheet Management

Total assets increased $41.22 million, or 2%, to $1.74 billion at June 30, 2021 from $1.70 billion at March 31, 2021.   The increase was primarily due to a $70.38 million increase in total cash and cash equivalents and a $5.70 million net increase in investment securities and CDs held for investment, and smaller increases in several other categories. This increase was partially offset by a $29.12 million decrease in net loans receivable (due to SBA PPP loan payoffs). Excluding SBA PPP loans, net loans receivable increased during the current quarter at an annualized rate of 6%. The increase in total assets was funded primarily by an increase in total deposits and by retained net income.

Loans

Primarily as a result of the successful processing of SBA PPP loan forgiveness applications totaling $42.54 million, net loans receivable decreased $29.12 million, or 3%, to $1.002 billion at June 30, 2021 from $1.031 billion at March 31, 2021. The decrease in SBA PPP loans was partially offset by a $6.25 million increase in commercial business loans, a $6.02 million increase in construction and land development loans and smaller increases in several other categories.

Loan Portfolio ($ in thousands)
	June 30, 2021							March 31, 2021							June 30, 2020
	Amount				Percent			Amount				Percent			Amount				Percent
Mortgage loans:
One- to four-family (a)	$	119,173			11	%		$	117,184			10	%		$	120,514			11	%
Multi-family		94,756			9				92,435			8				79,468			7
Commercial		458,889			41				461,966			40				455,454			40
Construction – custom and owner/builder		105,484			9				105,305			9				134,709			12
Construction – speculative one-to four-family		18,038			2				17,289			2				12,136			1
Construction – commercial		43,879			4				42,340			4				33,166			3
Construction – multi-family		45,624			4				44,266			4				27,449			2
Construction – land
Development		4,434			—				2,238			—				6,132			1
Land		18,289			2				19,041			2				27,009			3
Total mortgage loans		908,566			82				902,064			79				896,037			80
Consumer loans:
Home equity and second mortgage		31,891			3				32,026			3				34,405			3
Other		2,725			—				2,756			—				3,552			—
Total consumer loans		34,616			3				34,782			3				37,957			3
Commercial loans:
Commercial business loans		72,890			6				66,645			6				71,586			6
SBA PPP loans		95,633			9				138,175			12				122,581			11
Total commercial loans		168,523			15				204,820			18				194,167			17
Total loans		1,111,705			100	%			1,141,666			100	%			1,128,161			100	%
Less:
Undisbursed portion of construction loans in process		(90,332	)						(90,550	)						(95,785	)
Deferred loan origination fees		(6,339	)						(6,999	)						(6,723	)
Allowance for loan losses		(13,469	)						(13,434	)						(12,894	)
Total loans receivable, net	$	1,001,565						$	1,030,683						$	1,012,759

_______________________
(a)   Does not include one- to four-family loans held for sale totaling $3,359, $8,455 and $9,837 at June 30, 2021, March 31, 2021 and June 30, 2020, respectively.  

The following table highlights nine commercial real estate (“CRE”) segments generally presumed to have the potential to be more adversely affected by work at home and COVID related social distancing practices than other segments of the loan portfolio.

CRE Portfolio Breakdown by Collateral ($ in thousands)
Collateral Type		Amount				Percent of CRE Portfolio			Percent of Total Loan Portfolio
Office buildings		$	74,439			16	%		7	%
Medical/dental offices			55,775			12			5
Other retail buildings			40,475			9			4
Hotels/motels			26,271			6			2
Restaurants			25,427			6			2
Nursing homes			18,902			4			2
Shopping centers			14,252			3			1
Churches			13,131			3			1
Mini-Storage			12,662			3			1
Additional CRE			177,555			38			16
Total CRE		$	458,889			100	%		41	%

Within Timberland’s commercial business loan portfolio (non-CRE) resides a segment of restaurant loans totaling $7.40 million in outstanding balances at June 30, 2021. As additional security for these loans, Timberland holds cash collateral of 25% of the segment’s associated outstanding loan balances. Unless prior arrangements are made, and Timberland consents, loans falling more than four weeks delinquent are eligible for purchase from Timberland’s portfolio in accordance with a Marketing and Servicing Agreement in existence since March 6, 2014.     

Timberland originated $146.60 million in loans (including $6.16 million of SBA PPP loans) during the quarter ended June 30, 2021, compared to $250.01 million (including $122.58 million of SBA PPP loans) for the comparable quarter one year ago and $167.15 million (including $58.70 million of SBA PPP loans) for the preceding quarter. Timberland continues to sell fixed-rate one- to four-family mortgage loans into the secondary market for asset-liability management purposes and to generate non-interest income. Timberland also periodically sells the guaranteed portion of SBA loans. During the current quarter, fixed-rate one- to four-family mortgage loans totaling $41.06 million were sold compared to $52.08 million for the comparable quarter one year ago and $41.29 million for the preceding quarter.

Timberland’s investment securities and CDs held for investment increased $5.70 million, or 4%, to $151.98 million at June 30, 2021, from $146.28 million at March 31, 2021. The increase was primarily due to the purchase of additional mortgage-backed investment securities and U.S. Treasury securities and was partially offset by CDs maturing during the quarter.

Timberland’s liquidity continues to remain strong. Liquidity, as measured by the sum of cash and cash equivalents, CDs held for investment, and available for sale investment securities, was 39.2% of total liabilities at June 30, 2021, compared to 36.1% at March 31, 2021, and 28.8% one year ago.  

Deposits

Total deposits increased $40.79 million, or 3%, during the current quarter to $1.52 billion at June 30, 2021, from $1.48 billion at March 31, 2021. The quarter’s increase consisted of a $26.14 million increase in NOW checking account balances, a $16.71 million increase in money market account balances, and a $4.37 million increase in savings account balances. These increases were partially offset by a $3.60 million decrease in non-interest-bearing demand account balances and a $2.82 million decrease in certificates of deposit account balances.

Deposit Breakdown ($ in thousands)
			June 30, 2021							March 31, 2021							June 30, 2020
			Amount				Percent			Amount				Percent			Amount				Percent
Non-interest-bearing demand			$	495,938			33	%		$	499,541			34	%		$	427,102			32	%
NOW checking				429,950			28				403,811			27				352,999			27
Savings				255,103			17				250,736			17				212,645			16
Money market				189,443			12				171,896			11				150,611			12
Money market – reciprocal				12,253			1				13,094			1				11,257			1
Certificates of deposit under $250				115,782			7				119,388			8				131,980			10
Certificates of deposit $250 and over				24,183			2				23,393			2				31,946			2
Total deposits			$	1,522,652			100	%		$	1,481,859			100	%		$	1,318,540			100	%

Shareholders’ Equity and Capital Ratios

Total shareholders’ equity increased $4.95 million, or 2%, to $203.49 million at June 30, 2021, from $198.54 million at March 31, 2021. The increase in shareholders’ equity was primarily due to net income of $7.02 million for the quarter, which was partially offset by the payment of $1.76 million in dividends to shareholders and the repurchase of 16,688 shares of the Company’s common stock for $469,000 (an average price of $28.08 per share). Timberland had 399,282 shares available to be repurchased on its existing stock repurchase plan at June 30, 2021.

Timberland remains well capitalized with a total risk-based capital ratio of 22.60% and a Tier 1 leverage capital ratio of 11.03% at June 30, 2021.

Asset Quality and Loan Deferrals

Timberland’s non-performing assets to total assets ratio improved to 0.14% at June 30, 2021, from 0.31% one year ago and 0.16% at March 31, 2021. There were net recoveries of $35,000 for the current quarter compared to net recoveries of $2,000 for the preceding quarter and net recoveries of $4,000 for the comparable quarter one year ago.   No provisions for loan losses were made during the current and preceding quarter compared to a $1.00 million provision for loan losses for the comparable quarter one year ago.

Timberland consistently worked with borrowers affected by the COVID-19 pandemic by offering loan deferral and forbearance plans during the pandemic.   One year ago, at June 30, 2020, Timberland had granted deferrals on 209 loans with balances aggregating to $135.83 million (13.4% of net loans receivable). Deferrals were primarily approved for 90-day periods with interest continuing to accrue or with interest scheduled to be paid monthly. However, nearly all borrowers that were granted deferrals have resumed making regular payments and as of June 30, 2021, only one loan remained on deferral status. The following table notes the single COVID-19 related loan still on deferral status as of June 30, 2021. Interest is being paid monthly on this loan.

COVID-19 Loan Modifications ($ in thousands)
Industry / Collateral Type		Amount				Percent of Net Loans Receivable
Hotel		$	1,703			0.17	%

The allowance for loan losses (“ALL”) as a percentage of loans receivable was 1.33% at June 30, 2021, compared to 1.26% one year ago and 1.29% at March 31, 2021. If SBA PPP loans, which are 100% SBA guaranteed, are excluded, the ALL to loans receivable (excluding SBA PPP loans) at June 30, 2021 was 1.46% (non-GAAP).  

The ALL as a percentage of loans receivable is also impacted by the loans acquired in the South Sound Acquisition. Included in the recorded value of loans acquired in acquisitions are net discounts which may reduce the need for an allowance for loan losses on such loans because they are carried at an amount below their outstanding principal balance. The initial recorded value of loans acquired in the South Sound Acquisition was $123.62 million and the related fair value discount was $2.08 million, or 1.68% of the loans acquired. The remaining fair value discount on loans acquired in the South Sound Acquisition was $499,000 at June 30, 2021. The allowance for loan losses to loans receivable (excluding SBA PPP loan balances and the remaining aggregate balance of the loans acquired in the South Sound Acquisition) was 1.53% (non-GAAP) at June 30, 2021.

The following table details the ALL as a percentage of loans receivable:

		June 30,			March 31,			June 30,
		2021			2021			2020
ALL to loans receivable		1.33	%		1.29	%		1.26	%
ALL to loans receivable (excluding SBA PPP loans) (non-GAAP)		1.46	%		1.48	%		1.43	%
ALL to loans receivable (excluding SBA PPP loans and South Sound Acquisition loans) (non-GAAP)		1.53	%		1.56	%		1.55	%

Total delinquent loans (past due 30 days or more) and non-accrual loans decreased $611,000, or 17%, to $2.94 million at June 30, 2021, from $3.55 million one year ago, and decreased $985,000, or 25%, from $3.93 million at March 31, 2021.   Non-accrual loans decreased $986,000, or 33%, to $2.03 million at June 30, 2021, from $3.02 million one year ago and decreased $276,000, or 12%, from $2.31 million at March 31, 2021

Non-Accrual Loans ($ in thousands)
	June 30, 2021						March 31, 2021						June 30, 2020
	Amount				Quantity		Amount				Quantity		Amount				Quantity
Mortgage loans:
One- to four-family	$411				2		$415				2		$927				5
Commercial		373			1			643			2			875			3
Land		169			2			173			2			185			2
Total mortgage loans		953			5			1,231			6			1,987			10
Consumer loans
Home equity and second
Mortgage		545			6			539			6			586			7
Other		18			2			8			1			10			1
Total consumer loans		563			8			547			7			596			8
Commercial business loans		513			7			527			7			432			6
Total loans	$2,029				20		$2,305				20		$3,015				24

OREO and other repossessed assets decreased 89% to $157,000 at June 30, 2021, from $1.47 million at June 30, 2020, and remained unchanged from $157,000 at March 31, 2021. At June 30, 2021, the OREO and other repossessed asset portfolio consisted of three individual land parcels. No OREO properties were sold during the quarter ended June 30, 2021.

OREO and Other Repossessed Assets ($ in thousands)
	June 30, 2021						March 31, 2021						June 30, 2020
	Amount				Quantity		Amount				Quantity		Amount				Quantity
Land	$	157			3		$	157			3		$	1,466			8
Total	$	157			3		$	157			3		$	1,466			8

Acquisition of South Sound Bank

On October 1, 2018, the Company completed the acquisition of South Sound Bank, a Washington-state chartered bank, headquartered in Olympia, Washington (“South Sound Acquisition”). The Company acquired 100% of the outstanding common stock of South Sound Bank, and South Sound Bank was merged into Timberland Bank and the Company. Pursuant to the terms of the merger agreement, South Sound Bank shareholders received 0.746 of a share of the Company’s common stock and $5.68825 in cash per share of South Sound Bank common stock. The Company issued 904,826 shares of its common stock (valued at $28,267,000 based on the Company’s closing stock price on September 30, 2018 of $31.24 per share) and paid $6,903,000 in cash in the transaction for total consideration paid of $35,170,000.

About Timberland Bancorp, Inc.

Timberland Bancorp, Inc., a Washington corporation, is the holding company for Timberland Bank. The Bank opened for business in 1915 and serves consumers and businesses across Grays Harbor, Thurston, Pierce, King, Kitsap and Lewis counties, Washington with a full range of lending and deposit services through its 24 branches (including its main office in Hoquiam).    

Disclaimer

Certain matters discussed in this press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to our financial condition, results of operations, plan, objectives, future performance or business. Forward-looking statements are not statements of historical fact, are based on certain assumptions and often include the words “believes,” “expects,” “anticipates,” “estimates,” “forecasts,” “intends,” “plans,” “targets,” “potentially,” “probably,” “projects,” “outlook” or similar expressions or future or conditional verbs such as “may,” “will,” “should,” “would” and “could.” Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, assumptions and statements about future economic performance. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the results anticipated or implied by our forward-looking statements, including, but not limited to: the effect of the novel coronavirus of 2019 (“COVID-19”) pandemic, including the Company’s credit quality and business operations, as well as its impact on general economic and financial market conditions and other uncertainties resulting from the COVID-19 pandemic, such as the extent and duration of the impact on public health, the U.S. and global economies, and consumer and corporate customers, including economic activity, employment levels and market liquidity; the credit risks of lending activities, including changes in the level and trend of loan delinquencies and write-offs and changes in our allowance for loan losses and provision for loan losses that may be impacted by deterioration in the housing and commercial real estate markets which may lead to increased losses and non-performing assets in our loan portfolio, and may result in our allowance for loan losses not being adequate to cover actual losses, and require us to materially increase our loan loss reserves; changes in general economic conditions, either nationally or in our market areas; changes in the levels of general interest rates, and the relative differences between short and long term interest rates, deposit interest rates, our net interest margin and funding sources; uncertainty regarding the future of the London Interbank Offered Rate (“LIBOR”), and the potential transition away from LIBOR toward new interest rate benchmarks; fluctuations in the demand for loans, the number of unsold homes, land and other properties and fluctuations in real estate values in our market areas; secondary market conditions for loans and our ability to sell loans in the secondary market; results of examinations of us by the Federal Reserve and our bank subsidiary by the Federal Deposit Insurance Corporation, the Washington State Department of Financial Institutions, Division of Banks or other regulatory authorities, including the possibility that any such regulatory authority may, among other things, institute a formal or informal enforcement action against us or our bank subsidiary which could require us to increase our allowance for loan losses, write-down assets, change our regulatory capital position or affect our ability to borrow funds or maintain or increase deposits or impose additional requirements or restrictions on us, any of which could adversely affect our liquidity and earnings; legislative or regulatory changes that adversely affect our business including changes in regulatory policies and principles, or the interpretation of regulatory capital or other rules including as a result of Basel III; the impact of the Dodd Frank Wall Street Reform and Consumer Protection Act and implementing regulations; our ability to attract and retain deposits; our ability to control operating costs and expenses; the use of estimates in determining fair value of certain of our assets, which estimates may prove to be incorrect and result in significant declines in valuation; difficulties in reducing risk associated with the loans on our consolidated balance sheet; staffing fluctuations in response to product demand or the implementation of corporate strategies that affect our work force and potential associated charges; disruptions, security breaches, or other adverse events, failures or interruptions in, or attacks on, our information technology systems or on the third-party vendors who perform several of our critical processing functions; our ability to retain key members of our senior management team; costs and effects of litigation, including settlements and judgments; our ability to implement our business strategies; our ability to manage loan delinquency rates; increased competitive pressures among financial services companies; changes in consumer spending, borrowing and savings habits; the availability of resources to address changes in laws, rules, or regulations or to respond to regulatory actions; our ability to pay dividends on our common and stock; adverse changes in the securities markets; inability of key third-party providers to perform their obligations to us; changes in accounting policies and practices, as may be adopted by the financial institution regulatory agencies or the Financial Accounting Standards Board (“FASB”), including additional guidance and interpretation on accounting issues and details of the implementation of new accounting methods; the economic impact of war or any terrorist activities; other economic, competitive, governmental, regulatory, and technological factors affecting our operations; pricing, products and services including the Coronavirus Aid, Relief, and Economic Security Act of 2020 (“CARES Act”), the Consolidated Appropriations Act, 2021 (“CAA”), and the American Rescue Plan Act of 2021; and other risks detailed in our reports filed with the Securities and Exchange Commission.

Any of the forward-looking statements that we make in this press release and in the other public statements we make are based upon management’s beliefs and assumptions at the time they are made. We do not undertake and specifically disclaim any obligation to publicly update or revise any forward-looking statements included in this report to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements or to update the reasons why actual results could differ from those contained in such statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking statements discussed in this document might not occur and we caution readers not to place undue reliance on any forward-looking statements. These risks could cause our actual results for fiscal 2021 and beyond to differ materially from those expressed in any forward-looking statements by, or on behalf of us, and could negatively affect the Company’s consolidated financial condition and results of operations as well as its stock price performance.

TIMBERLAND BANCORP INC. AND SUBSIDIARY CONSOLIDATED STATEMENTS OF INCOME			Three Months Ended
($ in thousands, except per share amounts)			June 30,				March 31,				June 30,
(unaudited)			2021				2021				2020
	Interest and dividend income
	Loans receivable		$	13,298			$	12,790			$	12,871
	Investment securities			292				284				345
	Dividends from mutual funds, FHLB stock and other investments			28				27				23
	Interest bearing deposits in banks			247				259				429
	Total interest and dividend income			13,865				13,360				13,668
	Interest expense
	Deposits			690				764				1,159
	Borrowings			18				29				29
	Total interest expense			708				793				1,188
	Net interest income			13,157				12,567				12,480
	Provision for loan losses			—				—				1,000
	Net interest income after provision for loan losses			13,157				12,567				11,480
	Non-interest income
	Service charges on deposits			948				941				858
	ATM and debit card interchange transaction fees			1,363				1,237				1,069
	Gain on sales of loans, net			1,607				1,758				2,141
	Bank owned life insurance (“BOLI”) net earnings			150				146				148
	Servicing income (expense) on loans sold, net			(9	)			(10	)			35
	Valuation recovery (allowance) on loan servicing rights, net			(179	)			438				—
	Recoveries on investment securities, net			6				3				6
	Other			380				373				598
	Total non-interest income, net			4,266				4,886				4,855
	Non-interest expense
	Salaries and employee benefits			4,554				4,778				4,570
	Premises and equipment			995				998				1,077
	Loss on disposition of premises and equipment, net			—				—				4
	Advertising			162				155				150
	OREO and other repossessed assets, net			5				(68	)			11
	ATM and debit card processing			464				445				405
	Postage and courier			141				149				137
	State and local taxes			284				255				255
	Professional fees			262				181				286
	FDIC insurance expense			100				105				143
	Loan administration and foreclosure			148				90				191
	Data processing and telecommunications			627				634				603
	Deposit operations			289				245				245
	Amortization of core deposit intangible (“CDI”)			90				91				101
	Other, net			492				493				483
	Total non-interest expense, net			8,613				8,551				8,661
	Income before income taxes			8,810				8,902				7,674
	Provision for income taxes			1,786				1,651				1,463
	Net income		$	7,024			$	7,251			$	6,211
	Net income per common share:
	Basic		$	0.84			$	0.87			$	0.75
	Diluted			0.83				0.86				0.74
	Weighted average common shares outstanding:
	Basic			8,365,350				8,331,121				8,309,947
	Diluted			8,465,393				8,444,798				8,378,983
TIMBERLAND BANCORP INC. AND SUBSIDIARY CONSOLIDATED STATEMENTS OF INCOME			Nine Months Ended
($ in thousands, except per share amounts)			June 30,								June 30,
(unaudited)			2021								2020
	Interest and dividend income
	Loans receivable		$	39,406							$	38,457
	Investment securities			877								1,274
	Dividends from mutual funds, FHLB stock and other investments			83								95
	Interest bearing deposits in banks			816								2,164
	Total interest and dividend income			41,182								41,990
	Interest expense
	Deposits			2,358								3,591
	Borrowings			76								37
	Total interest expense			2,434								3,628
	Net interest income			38,748								38,362
	Provision for loan losses			—								3,200
	Net interest income after provision for loan losses			38,748								35,162
	Non-interest income
	Service charges on deposits			2,943								3,136
	ATM and debit card interchange transaction fees			3,755								3,178
	Gain on sales of loans, net			5,367								3,829
	BOLI net earnings			445								442
	Servicing income (expense) on loans sold, net			(4	)							171
	Valuation recovery (allowance) on loan servicing rights, net			23								(23	)
	Recoveries on investment securities, net			14								113
	Other			1,168								1,627
	Total non-interest income, net			13,711								12,473
	Non-interest expense
	Salaries and employee benefits			13,944								13,913
	Premises and equipment			2,949								2,914
	Gain on disposition of premises and equipment, net			—								(98	)
	Advertising			472								493
	OREO and other repossessed assets, net			(89	)							60
	ATM and debit card processing			1,341								1,203
	Postage and courier			428								416
	State and local taxes			822								705
	Professional fees			675								766
	FDIC insurance expense (credit)			301								116
	Loan administration and foreclosure			319								358
	Data processing and telecommunications			1,868								1,702
	Deposit operations			818								836
	Amortization of CDI			271								304
	Other, net			1,455								1,631
	Total non-interest expense, net			25,574								25,319
	Income before income taxes			26,885								22,316
	Provision for income taxes			5,320								4,404
	Net income		$	21,565							$	17,912
	Net income per common share:
	Basic		$	2.59							$	2.15
	Diluted			2.55								2.12
	Weighted average common shares outstanding:
	Basic			8,336,590								8,331,908
	Diluted			8,440,861								8,437,030

TIMBERLAND BANCORP INC. AND SUBSIDIARY CONSOLIDATED BALANCE SHEETS
($ in thousands, except per share amounts) (unaudited)			June 30,				March 31,				June 30,
			2021				2021				2020
Assets
Cash and due from financial institutions			$	25,387			$	21,707			$	24,691
Interest-bearing deposits in banks				478,339				411,635				246,953
	Total cash and cash equivalents			503,726				433,342				271,644
Certificates of deposit (“CDs”) held for investment, at cost				31,218				39,674				72,014
Investment securities:
	Held to maturity, at amortized cost			52,314				36,465				30,660
	Available for sale, at fair value			67,491				69,184				41,914
Investments in equity securities, at fair value				960				957				977
FHLB stock				2,103				2,303				1,922
Other investments, at cost				3,000				3,000				3,000
Loans held for sale				3,359				8,455				9,837
Loans receivable				1,015,034				1,044,117				1,025,653
Less: Allowance for loan losses				(13,469	)			(13,434	)			(12,894	)
	Net loans receivable			1,001,565				1,030,683				1,012,759
Premises and equipment, net				22,519				22,763				23,119
OREO and other repossessed assets, net				157				157				1,466
BOLI				22,041				21,891				21,447
Accrued interest receivable				4,260				4,471				4,614
Goodwill				15,131				15,131				15,131
CDI				1,354				1,444				1,727
Loan servicing rights, net				3,548				3,604				3,073
Operating lease right-of-use assets				2,360				2,436				2,662
Other assets				3,354				3,284				3,676
	Total assets		$	1,740,460			$	1,699,244			$	1,521,642
Liabilities and shareholders’ equity
Deposits: Non-interest-bearing demand			$	495,938			$	499,541			$	427,102
Deposits: Interest-bearing				1,026,714				982,318				891,438
	Total deposits			1,522,652				1,481,859				1,318,540
Operating lease liabilities				2,432				2,499				2,695
FHLB borrowings				5,000				10,000				10,000
Other liabilities and accrued expenses				6,884				6,343				7,601
	Total liabilities			1,536,968				1,500,701				1,338,836
Shareholders’ equity
Common stock, $.01 par value; 50,000,000 shares authorized;          8,353,969 shares issued and outstanding – June 30, 2021          8,361,457 shares issued and outstanding – March 31, 2021          8,310,793 shares issued and outstanding – June 30, 2020				42,624				42,949				42,352
Retained earnings				160,739				155,473				140,478
Accumulated other comprehensive income (loss)				129				121				(24	)
	Total shareholders’ equity			203,492				198,543				182,806
	Total liabilities and shareholders’ equity		$	1,740,460			$	1,699,244			$	1,521,642

KEY FINANCIAL RATIOS AND DATA		Three Months Ended
($ in thousands, except per share amounts) (unaudited)		June 30,				March 31,				June 30,
		2021				2021				2020
PERFORMANCE RATIOS:
Return on average assets (a)			1.63	%			1.75	%			1.70	%
Return on average equity (a)			14.02	%			14.89	%			13.83	%
Net interest margin (a)			3.22	%			3.21	%			3.63	%
Efficiency ratio			49.43	%			48.99	%			49.96	%
		Nine Months Ended
		June 30,								June 30,
		2021								2020
PERFORMANCE RATIOS:
Return on average assets (a)			1.74	%							1.79	%
Return on average equity (a)			14.76	%							13.53	%
Net interest margin (a)			3.30	%							4.08	%
Efficiency ratio			48.75	%							49.81	%
		June 30,				March 31,				June 30,
		2021				2021				2020
ASSET QUALITY RATIOS AND DATA:
Non-accrual loans		$	2,029			$	2,305			$	3,015
Loans past due 90 days and still accruing			—				—				—
Non-performing investment securities			179				188				228
OREO and other repossessed assets			157				157				1,466
Total non-performing assets (b)		$	2,365			$	2,650			$	4,709
Non-performing assets to total assets (b)			0.14	%			0.16	%			0.31	%
Net charge-offs (recoveries) during quarter		$	(35	)		$	(2	)		$	(4	)
ALL to non-accrual loans			664	%			583	%			428	%
ALL to loans receivable (c)			1.33	%			1.29	%			1.26	%
ALL to loans receivable (excluding SBA PPP loans) (d) (non-GAAP)			1.46	%			1.48	%			1.43	%
ALL to loans receivable (excluding SBA PPP loans and South Sound Acquisition loans) (d) (e) (non-GAAP)			1.53	%			1.56	%			1.55	%
Troubled debt restructured loans on accrual status (f)		$	2,380			$	2,864			$	2,876
CAPITAL RATIOS:
Tier 1 leverage capital			11.03	%			11.19	%			11.55	%
Tier 1 risk-based capital			21.34	%			19.47	%			19.39	%
Common equity Tier 1 risk-based capital			21.34	%			19.47	%			19.39	%
Total risk-based capital			22.60	%			20.72	%			20.65	%
Tangible common equity to tangible assets (non-GAAP)			10.85	%			10.81	%			11.03	%
BOOK VALUES:
Book value per common share		$	24.36			$	23.75			$	22.00
Tangible book value per common share (g)			22.39				21.76				19.97

________________________________________________

(a) Annualized
(b) Non-performing assets include non-accrual loans, loans past due 90 days and still accruing, non-performing investment securities and OREO and other repossessed assets. Troubled debt restructured loans on accrual status are not included.
(c) Does not include loans held for sale and is before the allowance for loan losses.
(d) Does not include PPP loans totaling $95,633, $138,175 and $122,581 at June 30, 2021, March 31, 2021 and June 30, 2020, respectively.
(e) Does not include loans acquired in the South Sound Acquisition totaling $40,622, $46,626 and $73,084 at June 30, 2021, March 31, 2021 and June 30, 2020, respectively.
(f) Does not include troubled debt restructured loans totaling $187, $192 and $207 reported as non-accrual loans at June 30, 2021, March 31, 2021 and June 30, 2020, respectively.
(g) Tangible common equity divided by common shares outstanding (non-GAAP).

AVERAGE BALANCES, YIELDS, AND RATES – QUARTERLY ($ in thousands) (unaudited)
	For the Three Months Ended
	June 30, 2021									March 31, 2021									June 30, 2020
	Amount				Rate					Amount				Rate					Amount				Rate
Assets
Loans receivable and loans held for sale	$	1,032,591			5.15		%			$	1,044,476			4.90		%			$	1,015,966			5.07		%
Investment securities and FHLB stock (1)		115,839			1.10						101,675			1.23						81,086			1.82
Interest-earning deposits in banks and CDs		487,508			0.20						422,286			0.24						278,158			0.62
Total interest-earning assets		1,635,938			3.39						1,568,437			3.41						1,375,210			3.97
Other assets		87,638									85,203									87,905
Total assets	$	1,723,576								$	1,653,640								$	1,463,115
Liabilities and Shareholders’ Equity
NOW checking accounts	$	416,234			0.13		%			$	394,612			0.16		%			$	332,502			0.26		%
Money market accounts		196,187			0.29						178,768			0.30						156,537			0.47
Savings accounts		253,147			0.08						236,504			0.08						199,054			0.11
Certificates of deposit accounts		141,301			1.02						146,065			1.19						168,368			1.68
Total interest-bearing deposits		1,006,869			0.27						955,949			0.32						856,461			0.54
Borrowings		5,769			1.25						10,003			1.17						10,000			1.17
Total interest-bearing liabilities		1,012,638			0.28						965,952			0.33						866,461			0.55
Non-interest-bearing demand deposits		499,383									482,528									406,396
Other liabilities		11,217									10,365									10,684
Shareholders’ equity		200,338									194,795									179,574
Total liabilities and shareholders’ equity	$	1,723,576								$	1,653,640								$	1,463,115
Interest rate spread					3.11		%							3.08		%							3.42		%
Net interest margin (2)					3.22		%							3.21		%							3.63		%
Average interest-earning assets to
average interest-bearing liabilities		161.55	%								162.37	%								158.72	%

 _____________________________________
(1) Includes other investments
(2) Net interest margin = annualized net interest income / average interest-earning assets

AVERAGE BALANCES, YIELDS, AND RATES – YEAR-TO-DATE ($ in thousands) (unaudited)
	For the Nine Months Ended
	June 30, 2021								June 30, 2020
	Amount				Rate				Amount				Rate
Assets
Loans receivable and loans held for sale	$	1,035,733			5.07		%		$	949,822			5.40		%
Investment securities and FHLB stock (1)		103,821			1.23					76,282			2.40
Interest-earning deposits in banks and CDs		427,881			0.25					226,129			1.28
Total interest-earning assets		1,567,435			3.50					1,252,233			4.47
Other assets		85,636								85,405
Total assets	$	1,653,071							$	1,337,638
Liabilities and Shareholders’ Equity
NOW checking accounts	$	396,140			0.16		%		$	310,717			0.29		%
Money market accounts		181,115			0.30					144,663			0.54
Savings accounts		237,456			0.08					184,076			0.10
Certificates of deposit accounts		147,530			1.20					168,148			1.75
Total interest-bearing deposits		962,241			0.33					807,604			0.59
Borrowings		8,592			1.17					4,234			1.17
Total interest-bearing liabilities		970,833			0.34					811,838			0.60
Non-interest-bearing demand deposits		476,628								339,460
Other liabilities		10,757								9,823
Shareholders’ equity		194,853								176,517
Total liabilities and shareholders’ equity	$	1,653,071							$	1,337,638
Interest rate spread					3.16		%						3.87		%
Net interest margin (2)					3.30		%						4.08		%
Average interest-earning assets to
average interest-bearing liabilities		161.45	%							154.25	%

_____________________________________
(1) Includes other investments
(2) Net interest margin = annualized net interest income / average interest-earning assets

Non-GAAP Financial Measures

In addition to results presented in accordance with generally accepted accounting principles (“GAAP”), this press release contains certain non-GAAP financial measures. Timberland believes that certain non-GAAP financial measures provide investors with information useful in understanding the Company’s financial performance; however, readers of this report are urged to review these non-GAAP financial measures in conjunction with GAAP results as reported.

Financial measures that exclude intangible assets are non-GAAP measures. To provide investors with a broader understanding of capital adequacy, Timberland provides non-GAAP financial measures for tangible common equity, along with the GAAP measure. Tangible common equity is calculated as shareholders’ equity less goodwill and CDI. In addition, tangible assets equal total assets less goodwill and CDI.

The following table provides a reconciliation of ending shareholders’ equity (GAAP) to ending tangible shareholders’ equity (non-GAAP) and ending total assets (GAAP) to ending tangible assets (non-GAAP).

($ in thousands)		June 30, 2021				March 31, 2021				June 30, 2020
Shareholders’ equity		$	203,492			$	198,543			$	182,806
Less goodwill and CDI			(16,485	)			(16,575	)			(16,858	)
Tangible common equity		$	187,007			$	181,968			$	165,948
Total assets		$	1,740,460			$	1,699,244			$	1,521,642
Less goodwill and CDI			(16,485	)			(16,575	)			(16,858	)
Tangible assets		$	1,723,975			$	1,682,669			$	1,504,784

Contact:

Michael R. Sand, President & CEO Dean J. Brydon, CFO (360) 533-4747 www.timberlandbank.com